Janssen-Cilag Ltd

50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Telephone: +44 (0)1494 567 567
Fax: +44 (0)1494 567 568
WWW: http://www.janssen-cilag.co.uk
Medical Information Direct Line: +44 (0)800 731 8450
Medical Information e-mail: medinfo@janssen-cilag.co.uk
Customer Care direct line: +44 (0)800 731 5550
Summary of Product Characteristics last updated on the eMC: 12/09/2008
SPC Concerta XL 27 mg Prolonged-Release Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 12/09/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 6.1 - List of Excipients
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04-Sep-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Change to section 2 – quantitative and qualitative composition

Addition of  information that lactose is an excipient

Change to section 4.1 – Therapeutic Indications

‘Drug’ now referred to as ‘medicinal product’ throughout the SPC

Change to section 4.2 – Posology and |Method of Administration

Safety statement referring to children under 6 moved to beginning of section 4.2

Change to section 4.3 – Contra-indications

Minor text changes

Change to section 4.4 – Special Warnings and Precautions for Use

Removal of reference to patients with renal or hepatic inpairtment’

Change to section 4.5 –Interaction with other medicinal products and other forms of interaction

Minor text changes

Change to section 4.6 – Pregnancy and Lactation

Minor text changes

Change to section 4.7 - Effects on Ability to Drive and Use Machines

Minor text changes

Change to section 4.8 – Undesirable effects

Change in order of undesirable effects according to frequency of reporting

Change to section 6.1 – List of Excipients

Minor text changes

Change to section 6.4 – Special Precautions for Storage

Addition of  ‘in order to protect from moisture’

Change to section 6.5 – Nature and Contents of Container

Addition of ‘silica gel’

Change to section 10 – Date of revision of the text

Change to 4th September 2008

Updated on 04/08/2008 and displayed until 12/09/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   29-Jul-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Change to section 7 – Marketing Authorisation Holder

Updated to High Wycombe address

Change to section 10 – Date of revision of the text

Updated to 29th July 2008

Updated on 18/07/2007 and displayed until 04/08/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
  • Change to joint SPC covering all presentations
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change to section 4.4 – Special Warnings and Precautions for Use

Addition of mania/aggression sub-headings & text

 

Change to section 4.8 – Undesirable effects

Major revision to update to 2005 SPC guidance

 

Change to section 10 – Date of revision of the text

Changed to 20th June 2007

 

Change to separate SPCs covering individual presentations                                                                                                                                                                                                      

 

Updated on 12/03/2007 and displayed until 18/07/2007
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   methylphenidate


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk